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Abstract
Background: In Zambia the first-line treatment for uncomplicated malaria is artemisinin
combination therapy (ACT), with artemether-lumefantrine currently being used. However, the
antifolate regimen, sulphadoxine-pyrimethamine (SP), remains the treatment of choice in children
weighing less than 5 kg and also in expectant mothers. SP is also the choice drug for intermittent
preventive therapy in pregnancy and serves as stand-by treatment during ACT stock outs. The
current study assessed the status of Plasmodium falciparum point mutations associated with
antifolate drug resistance in the area around Macha.
Methods: A representative sample of 2,780 residents from the vicinity of Macha was screened for
malaria by microscopy. At the same time, blood was collected onto filter paper and dried for
subsequent P. falciparum DNA analysis. From 188 (6.8%) individuals that were thick film-positive, a
simple random sub-set of 95 P. falciparum infections were genotyped for DHFR and DHPS antifolate
resistance mutations, using nested PCR and allele-specific restriction enzyme digestion.
Results: Plasmodium falciparum field samples exhibited a high prevalence of antifolate resistance
mutations, including the DHFR triple (Asn-108 + Arg-59 + Ile-51) mutant (41.3%) and DHPS double
(Gly-437 + Glu-540) mutant (16%). The quintuple (DHFR triple + DHPS double) mutant was found
in 4 (6.5%) of the samples. Levels of mutated parasites showed a dramatic escalation, relative to
previous surveys since 1988. However, neither of the Val-16 and Thr-108 mutations, which jointly
confer resistance to cycloguanil, was detectable among the human infections. The Leu-164
mutation, associated with high grade resistance to both pyrimethamine and cycloguanil, as a
multiple mutant with Asn-108, Arg-59 and (or) Ile-51, was also absent.
Conclusion: This study points to escalating levels of P. falciparum antifolate resistance in the
vicinity of Macha. Continued monitoring is recommended to ensure timely policy revisions before
widespread resistance exacts a serious public health toll.
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Background
Malaria kills an estimated 0.7 to 2.7 million people, of
which 75% are African children [1]. Finding effective drug
treatment is a necessity; however, drug resistance is an
increasing problem, which poses a great challenge for
control. Tanzania first reported emerging SP resistance in
Africa around 1994 – 1995 [2,3].
During the period of 2000–2005, Zambia revised its
national malaria drug treatment policy to adopt artemisinin combination therapy (ACT) as the standard of care
nationally [4] This essentially led to the replacement of
chloroquine and sulphadoxine-pyrimethamine (SP)
monotherapy with ACT. Nevertheless, SP is still widely
used and remains the drug of choice to treat uncomplicated malaria in children weighing less than 5 kg and in
pregnant women. SP is also the drug of choice for intermittent presumptive therapy in pregnancy (IPTp) and
serves as stand-by treatment during stock-outs of ACT's.
Moreover, recent efforts to scale-up malaria control in
endemic countries, including increased support for commodities and health systems, is resulting in greater access
to and a vastly increased use of antimalarial medicines [4].
This leads to a much higher degree of drug pressure on the
parasite which will almost certainly increase the likelihood of selecting for resistant parasite genotypes.
Resistance to antifolate drugs is associated with point
mutations in the dihydrofolate reductase domain of the
dihydrofolate-thymidylate synthetase (DHFR-TS) gene
and dihydropteroate synthase region of the pyrophosphokinase-dihydropteroate synthetase (PPK-DHPS) gene
of the malaria parasite. Sulpha drugs act by selectively
inhibiting the PPK-DHPS enzyme in the folate pathway of
the parasite [5]. The genes encoding the PPK-DHPS and
DHFR-TS enzymes have been sequenced in P. falciparum
and point mutations have been identified which are associated with in vitro pyrimethamine-sulphadoxine resistance. Point mutations in the following codons of the
DHPS domain are known to confer resistance to sul-

Figure
Plasmodium
Macha,
1988,
2000,
1988
2 falciparum
2003
– 2006
and(n2006)
DHPS
= 110,mutations
49, 25 andin95,
therespectively
vicinity of for
Plasmodium falciparum DHPS mutations in the vicinity of
Macha, 1988 – 2006 (n = 110, 49, 25 and 95, respectively for
1988, 2000, 2003 and 2006).

phadoxine: Ser-436 to Ala-436; Ala-437 to Gly-437; Lys540 to Glu-540; Ala-613 to Ser-613 or Thr-613. Resistance
to pyrimethamine is conferred by point mutations in the
DHFR domain, with the associated amino acid changes as
Ala-16 to Val-16, Asn-51 to Ile-51; Cys-59 to Arg-59; Ser108 to Asn-108/Thr-108, and Ile-164 to Leu-164. SP
resistance is therefore attributed to parasites that carry
point mutations at codons 16, 51, 59, 108 and 164 of the
DHFR gene and is further augmented by point mutations
at codons 436, 437, 540, 581 and 613 of the DHPS gene
[6-8]. The present study assessed the prevalence of DHFR
and DHPS mutations in P. falciparum isolates from residents of the Macha area in Southern Province of Zambia.

Methods
Study area and population
The study was conducted in a 2,000 km2 area around
Macha, approximately 75 km north of Choma in Zambia's southern province. The area lies 900 – 1,000 m
above sea level and traditionally has experienced hyperendemic malaria transmission. Residents in this community
are primarily subsistence farmers of the BaTonga tribe.
Study design and data collection
The study was a prospective cross-sectional survey, based
on willing participants of all ages. The area around Macha
was divided into 80 geographical grids of 25 km2 apiece,
in extent. Using a simple random sampling procedure, ten
such grids were chosen, followed by one headman area
(an administrative unit comprising an average of 270 residents in a group of households, which report to one
elected household head, called a headman) from 2–5 possible per grid. By prior arrangement, following permission
from the relevant chiefs and headmen, all willing individuals from each of the ten chosen headmen areas, in turn,
assembled at a central location of their choice for malaria
screening by microscopy. Thick blood films and filter
paper blood spots were collected by finger-prick from a
total sample of 2,780 residents. One hundred and eighty-
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Table 1: Antifolate resistance multiple mutants in the vicinity of Macha, 1988 – 2006.

Mutant
Survey Year

DHFR triple

DHPS double

DHFR/DHPS quintuple

N

1988
2000
2003
2006

0 (0.0%)
0 (0.0%)
10 (40.0%)
38 (41.3%)

0 (0.0%)
1 (2.0%)
2 (8.0%)
10 (16.1%)

0 (0.0%)
0 (0.0%)
1 (4.0%)
4 (6.5%)

110
49
25
95

eight (188) samples were thick film-positive. A simple
random sub-set of 95 samples were subsequently genotyped for P. falciparum DHFR and DHPS antifolate resistance mutations.
DNA extraction and molecular analysis
Parasite DNA was extracted using the chelex method[9]
(chelex 100 resin (Biorad®) was employed). Antifolate
resistance polymorphisms in DHFR and DHPS genes were
detected by nested PCR and allele specific restriction
enzyme digestion as previously described [10]. PCR
amplicon and restriction fragments were resolved by electrophoresis on 2% ethidium bromide agarose gels and visualized by UV transillumination on a 1D Kodak (EDAS
290) imaging system.
Ethics
Permission for the study was sought from resident chiefs,
headmen, household heads and study participants themselves (or guardians in the case of children). The study was
approved by the University of Zambia Research Ethics
Committee (UNZA-REC).

Results
Virtually all the P. falciparum infections assayed (97.5%)
bore the pyrimethamine-resistant DHFR Asn-108 mutation, 17.5% occurring as a mixture with wild type Ser-108.
High levels of the DHFR Ile-51 and Arg-59 mutations were
also found (Figure 1). Albeit less prevalent, DHPS mutations occurred at codons 436, 437 and 540 (Figure 2).
There were appreciable multiple antifolate resistance
mutants, including DHFR triple (Ile-51/Arg-59/Asn-108),
DHPS double (Gly-437 + Glu-540) and the quintuple
(DHFR triple + DHPS double) mutant (Table 1).
Antifolate resistance mutations have evidently escalated
over the years, since previous surveys (Thuma et al unpublished data) in the area from 1988 (Figure 1 – Figure 2,
Table 1). The odds of infections carrying Ile-51, Cys-59
and Asn-108, have increased 15× (OR [95% CI]: 14.9
[6.02–36.89], p < 0.001), 11× (OR [95% CI]: 10.6 [5.13–
21.98]), and 18× (OR [95% CI]: 18.4 [9.00–37.59]),
respectively for 2006 relative to 1988.

Absent among the infections were the DHFR Thr-108, Val16 and Leu-164 mutations. The DHPS Phe-436, Ser/Thr613 and Gly-581 mutations were not found, and there
were no DHFR quadruple mutants among the field samples.

Discussion
This study documents the current status of P. falciparum
antifolate resistance mutations in an area of the Southern
Province of Zambia. The results show elevated levels of
DHFR mutations, with practically saturated (pyrimethamine-resistant) Asn-108, and multiple mutants setting
in.
It is evident that antifolate resistance mutants have been
escalating dramatically among local P. falciparum infections since 1988. This trend can be expected from drug
selection pressure due to SP use over the years. Originally
SP was second line medication in Zambia for suspected
chloroquine-resistant cases. However, in 2003, SP was
adopted as the drug of choice for treatment of children
weighing less than 5 kg and pregnant women. The antifolate combination also continues to serve as the stand-by
drug treatment during shortages of ACT, and remains the
drug of choice for IPTp. Evolution of resistance to SP upon
widespread use of the drug has typically developed more
rapidly than to chloroquine [11,12]. Hence antifolate
resistance will likely continue to intensify under the
present conditions.
The rising prevalence of multiple mutants may well point
to the beginning of the end for SP in vivo efficacy, since
these correlate more closely with therapeutic failure. The
quintuple mutant is of major concern, although it was
only found in 7% of the infections so far. Nevertheless,
the right combinations of P. falciparum DHFR and DHPS
point mutations that can cause clinical resistance to antifolates are already prevalent. These prevailing mutated
parasite profiles may explain localized malaria outbreaks
that now consistently occur at health centers and clinics
during ACT stock-outs, especially when there is reversion
to use of SP. Avoidance of ACT shortages at health centers
and clinics is, therefore, paramount. Continued molecular
surveillance and in vivo therapeutic efficacy assessments
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are recommended to help ensure appropriate policy revisions before widespread therapeutic failure claims a serious public health toll.
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